Holen Sie sich die Stockscreener-App
1.12
7.44%
-0.09
Handel nachbörslich:
1.14
0.02
+1.79%
Schlusskurs vom Vortag:
$1.21
Offen:
$1.22
24-Stunden-Volumen:
533.14K
Relative Volume:
0.85
Marktkapitalisierung:
$17.04M
Einnahmen:
$486.00K
Nettoeinkommen (Verlust:
$-28.43M
KGV:
-0.3973
EPS:
-2.8189
Netto-Cashflow:
$-26.75M
1W Leistung:
-13.18%
1M Leistung:
+25.84%
6M Leistung:
-58.82%
1J Leistung:
-46.67%
1-Tages-Spanne:
$1.12
$1.23
1-Wochen-Bereich:
$1.10
$1.38
52-Wochen-Spanne:
$0.85
$4.30
Vyne Therapeutics Inc Stock (VYNE) Company Profile
Firmenname
Vyne Therapeutics Inc
Sektor
Branche
Telefon
800-775-7936
Adresse
685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER
Vergleichen Sie VYNE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VYNE
Vyne Therapeutics Inc
|
1.12 | 21.50M | 486.00K | -28.43M | -26.75M | -2.8189 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Vyne Therapeutics Inc Stock (VYNE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-18 | Eingeleitet | BTIG Research | Buy |
| 2021-12-06 | Fortgesetzt | H.C. Wainwright | Buy |
Vyne Therapeutics Inc Aktie (VYNE) Neueste Nachrichten
What drives VYNE Therapeutics Inc. stock priceOutstanding capital returns - jammulinksnews.com
Is VYNE Therapeutics Inc. a good long term investmentFree Bull & Bear Market Updates - jammulinksnews.com
What analysts say about VYNE Therapeutics Inc. stockSuperior portfolio returns - Autocar Professional
VYNE Therapeutics Inc. Stock Analysis and ForecastSuperior profit margins - jammulinksnews.com
Does VYNE Therapeutics Inc. stock pay reliable dividendsFree Capital Allocation Plans - Newser
How VYNE Therapeutics Inc. stock performs during market volatilityShort Term High Return Strategy - Newser
Why VYNE Therapeutics Inc. stock attracts strong analyst attentionAlpha Stock Ideas - Newser
What makes VYNE Therapeutics Inc. stock price move sharplyIntraday Trade Ideas - Newser
VYNE Therapeutics Inc. (VYNE) Gets Buy Reaffirmation on Pipeline Progress - MSN
VYNE Therapeutics: A High-Stakes Gamble on Vitiligo and Psoriasis - AInvest
Promising Potential of VYNE Therapeutics’ Repibresib Gel in Phase IIb Study - TipRanks
VYNE Therapeutics (NASDAQ:VYNE) Stock Price Down 9.5% – Should You Sell? - Defense World
VYNE Unblinds Early VYN202 Data After Safety Pause - Dermatology Times
BTIG reiterates Buy rating on VYNE Therapeutics stock ahead of vitiligo trial data - Investing.com Canada
H.C. Wainwright reiterates Buy rating on VYNE Therapeutics stock amid clinical hold update - Investing.com Canada
NOVT secures new $1B credit facility, extends maturity to 2030 | VYNE SEC FilingForm 4 - Stock Titan
VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202 - The Manila Times
VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202 | VYNE Stock News - GuruFocus
VOR Skyrockets On Ex-China Rights To Autoimmune Drug, ADIL To Face FDA On Jul.29, PSTV Jumps 14% - Nasdaq
Celebrating World Vitiligo Day 2025 with Dermatology Times - Dermatology Times
Vitiligo Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight - The Globe and Mail
Short Interest in VYNE Therapeutics Inc. (NASDAQ:VYNE) Increases By 46.8% - Defense World
Jane Street Group LLC Invests $68,000 in VYNE Therapeutics Inc. (NASDAQ:VYNE) - Defense World
Northern Trust Corp Has $80,000 Stock Holdings in VYNE Therapeutics Inc. (NASDAQ:VYNE) - Defense World
VYNE Stock Touches 52-Week Low at $0.96 Amid Market Challenges By Investing.com - Investing.com South Africa
VYNE Therapeutics (NASDAQ:VYNE) Upgraded at Wall Street Zen - Defense World
VYNE Stock Touches 52-Week Low at $0.96 Amid Market Challenges - Investing.com India
VYNE Therapeutics (NASDAQ:VYNE) Cut to Sell at Wall Street Zen - Defense World
VYNE Stock Touches 52-Week Low at $1.17 Amid Market Challenges - Investing.com
VYNE Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE) and CVRx (CVRX) - The Globe and Mail
VYNE Therapeutics Reports Q1 2025 Financial Results - TipRanks
VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
VYNE Therapeutics: Strong Financial Position and Promising Drug Pipeline Justify Buy Rating - TipRanks
Vyne Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
VYNE Therapeutics Inc Q1 2025 Earnings: EPS of -$0.20 Beats Estimate, Revenue of $0.2 Million Exceeds Forecast - GuruFocus
VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update - The Manila Times
Renaissance Technologies LLC Decreases Stake in VYNE Therapeutics Inc. (NASDAQ:VYNE) - Defense World
Finanzdaten der Vyne Therapeutics Inc-Aktie (VYNE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):